BACKGROUND: Aprotinin is superior to other antifibrinolytic drugs for preventing major
blood loss after cardiac surgery but may also increase perioperative mortality. It remains …

BACKGROUND: Our aim was to investigate postoperative complications and mortality after
administration of aprotinin compared to tranexamic acid in an unselected, consecutive …

Background Antifibrinolytic agents are commonly used during cardiac surgery to minimize
bleeding and to reduce exposure to blood products. We sought to determine whether …

BACKGROUND: Cardiac surgery with cardiopulmonary bypass may result in excessive
fibrinolysis and platelet (PLT) dysfunction, resulting in impaired hemostasis and excessive …

Excessive bleeding during and after cardiac surgery is a serious complication that exposes
patients both to the risks of transfusion of blood products and to those associated with …

To determine whether aprotinin increases mortality as compared with tranexamic acid in
cardiac surgery, we performed a meta-analysis of randomized head-to-head trials. All …

Background The majority of patients undergoing surgical treatment for ST-elevation
myocardial infarction receive antifibrinolytic therapy to limit blood loss. This approach …

Background To compare the effect of aprotinin with the effect of lysine analogues
(tranexamic acid and ε-aminocaproic acid) on early mortality in three subgroups of patients …

Background: Because of recent concerns about the safety of aprotinin, we updated our 2007
Cochrane review that compared the relative benefits and risks of aprotinin and the lysine …

Background: Aprotinin is the only Food and Drug Administration-approved agent to reduce
haemorrhage related to cardiac surgery and its safety and efficacy has been extensively …